An interventional study of Laser Speckle Flowgraphy in Glaucoma, Primary Open Angle, sponsored by Augenabteilung Allgemeines Krankenhaus Linz. Status unknown at 1 site in Austria. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-24.
Sponsored by Augenabteilung Allgemeines Krankenhaus Linz · Not applicable, Interventional, and Diagnostic
Among 30 studies in Glaucoma, Open-Angle with a site in Austria — 6 open to participants now, 7 under way, none of them phase 3. Glaucoma, Open-Angle · Austria.
Among the 30 studies in Glaucoma, Open-Angle with a site in Austria, this one is the 16th largest by enrollment of the 22 interventional ones, is one of 4 that started in 2017, is one of 10 with no phase, and was the 21st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's enrollment of 40 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →6 of the 30 studies in Glaucoma, Open-Angle with a site in Austria are open now, in 8 countries. Each count lists the studies.
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →30 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2017.
Median enrollment 91 across the 22 interventional studies, 310 across the 8 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
14 of 30 have an industry lead sponsor. The 10 most frequent:
Augenabteilung Allgemeines Krankenhaus Linz is the lead sponsor of 7 studies on the registry; none are open to participants now.
Augenabteilung Allgemeines Krankenhaus Linz has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma, Open-Angle with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844292Medical University of GrazEvaluation of Microinvasive Glaucoma Surgery: MINIject® Versus Hydrus® Microstent in Combination With Cataract Surgery | 2027-03-03 |
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Among the 30 studies in Glaucoma, Open-Angle with a site in Austria, from their registry updates:
Glaucoma is the second leading cause of blindness worldwide. Literature shows increasing evidence that dysfunction of ocular microcirculation in the optic nerve influences the progression of glaucoma. Laser speckle flowgraphy (LSFG) represents a non-invasive method to quantify ocular perfusion also at the ONH. LSFG enables noninvasive quantification of microcirculation of the optic disc in Japanese glaucoma patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
Mean blur ratio (LSFG)
Time frame: 4 seconds
Pulse-waveform parameters (LSFG)
Time frame: 4 seconds
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for Nov 2017, 10 months after the start.
Of 100 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 57. This study's planned 10 months is below that.
Counting every sponsor, half of 170 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Augenabteilung Allgemeines Krankenhaus Linz